Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Christian Glennie
STIF
Christian Glennie
Stifel Nicolaus
Wall Street Analyst
Not yet ranked — too few measurable calls.
100%
Success Rate
+208.8%
Average Return
1 of 1 calls profitable · +176.7% vs benchmark
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 100% of Christian Glennie's ratings turned a profit when each position was held for 1 year — averaging +208.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

6 Buy 1 Hold 0 Sell
Christian's Stock Coverage 17 ratings · 2026-06-20
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
GB:AMS
Advanced Medical Solutions
 May 21, 2026 BUY Strong Buy
+14.1% avg upside
3 analysts
$245.00
4.23% Upside
 ·
GB:CTEC
ConvaTec
 Mar 11, 2026 BUY Strong Buy
+41.3% avg upside
16 analysts
$315.00
52.26% Upside
 ·
PLLWF
Polarean Imaging
 Sep 25, 2025 BUY Strong Buy
+702.1% avg upside
1 analyst
$0.05
702.05% Upside
 ·
GB:DXRX
Diaceutics
 Sep 23, 2025 BUY Strong Buy
+38.5% avg upside
2 analysts
$225.00
52.08% Upside
 ·
GB:EKF
EKF Diagnostics Holdings
 Sep 16, 2025 BUY Strong Buy
+35.2% avg upside
1 analyst
$35.00
35.23% Upside
 ·
GB:GNS
Genus plc
 Sep 09, 2025 HOLD Buy
+3959.4% avg upside
3 analysts
$2300.00
4.28% Upside
 ·
INDV
Indivior
 Apr 24, 2025 BUY Strong Buy
+2.1% avg upside
9 analysts
$14.56
61.98% Downside
 +208.8%
GB:HIK
Hikma Pharmaceuticals
 Apr 24, 2025 BUY Buy
+64.1% avg upside
7 analysts
$2650.00
81.80% Upside
 ·
GB:UPR
Uniphar PLC
 Mar 21, 2025 BUY Strong Buy
+0.9% avg upside
3 analysts
$411.99
2.55% Upside
 ·
DE:4YL
Nanoform Finland Oyj
 Nov 19, 2024 BUY Strong Buy
+362.4% avg upside
1 analyst
$4.00
362.41% Upside
 ·
NL:PHARM
Pharming Group
 Jun 04, 2024 BUY Strong Buy
+192.0% avg upside
4 analysts
 — ·
GB:AVCT
Avacta Group plc
 May 23, 2024 BUY Strong Buy
+43.8% avg upside
1 analyst
$105.00
43.79% Upside
 ·
ES:PHM
Pharma Mar SA
 Nov 11, 2020 HOLD Buy
+57.6% avg upside
4 analysts
$109.00
56.81% Upside
 ·
GB:AGY
Allergy Therapeutics
 Jul 25, 2018 BUY Strong Buy
+29914.2% avg upside
2 analysts
$4155.96
59270.90% Upside
 ·
GB:EMVC
NetScientific
 May 24, 2018 BUY Strong Buy
+10798.4% avg upside
1 analyst
$5667.22
10798.44% Upside
 ·
GB:IPO
IP Group plc
 Jun 08, 2017 BUY Strong Buy
+7352.8% avg upside
3 analysts
$14205.83
21856.45% Upside
 ·
GB:OBD
Oxford BioDynamics
 May 18, 2017 BUY Strong Buy
+8014151.6% avg upside
1 analyst
$13223.52
8014151.63% Upside
 ·
🔒 12 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Christian Glennie — Frequently Asked Questions
How accurate are Christian Glennie's stock ratings?
Based on the calls 13Foresight could measure, about 100% of Christian's ratings were profitable over a one-year hold, with an average return of +208.8% per rating, or +177.1% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Christian ranked on 13Foresight?
Christian Glennie is currently ranked unranked . Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Christian cover?
Christian most recently has ratings on GB:AMS, GB:CTEC, PLLWF, GB:DXRX, GB:EKF, GB:GNS, INDV, GB:HIK, GB:UPR, DE:4YL, NL:PHARM, GB:AVCT and 5 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.